Following swiftly on Upjohn's court win in the UK regarding libel by the BBC and a newspaper interview (Marketletter June 6), a federal district court in Worcester, Massachusetts, USA, has directed a jury to return a verdict in favor of Upjohn in a civil trial involving the company's anxiolytic Halcion (triazolam). The law suit alleged that a Massachusetts man's suicide had been caused by his use of the drug.
In March of this year, a federal jury in Houston, Texas, also found in favor of Upjohn, rejecting claims that Halcion caused aggressive and suicidal behavior, and in March 1993, a San Antonio, Texas, jury rejected a claim that Halcion caused abnormal behavior. Upjohn notes that these decisions follow conclusions in 1989 and 1992 by Food and Drug Administration advisory committees that Halcion is safe and effective when taken according to its approved labelling.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze